|Day Low/High||64.61 / 65.29|
|52 Wk Low/High||54.07 / 67.16|
The differences in approach between the two most basic strategies for how to grow an economy are as stark as the division they cause among economists.
Bristol-Myers offers a terrific combination of yield, dividend safety, and dividend growth for income-focused investors.
Prices have rallied from early March and are in a position to test their January highs.
At current levels BMY is sort-of in no man's land - not bullish and not bearish.
Exelixis and Ultragenyx Pharmaceutical are cash rich mid-caps that don't look overbought.
There is a point where if longer-dated yields move high enough, defensive-minded investors will be drawn from equities to debt securities.
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
Traders should stay long and consider increasing their exposure.
A correction in EBS could soon set up an attractive opportunity.
This Friday several banks begin the unofficial kickoff of 'earnings season'.
I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
The technical patterns of Boeing, Bristol-Myers Squibb and DraftKings are worth tracking for potential buys.
I am flat LLY for now. Let's see how the shares behave around the technicals. Then we'll make an equity decision.
The most important market takeaway right now is that both the Nasdaq Composite and S&P 500 have filled their respective gaps and retaken their 50-day simple moving averages.
These are the top five misconceptions about presidential elections -- and the stocks that you should look at right now.
The market is reflecting a triumph of big business over small business, and here's what that means for individual stocks.
Aggressive traders could go long BMY at two price levels.
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
It's remarkable to see such excitement based on totally contradictory theories and themes.
BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.
This diversification strategy lets you to capture stock market upside, while not risking your shirt.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
The market's performance in the three months leading up to a presidential election has displayed an uncanny ability to forecast which party will win the White House.
BMY sees reason for optimism over the final half of the year.
Check out the Dow Transports and the Dow Industrials.